<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SPIRIVA - tiotropium bromide monohydrate capsule </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use SPIRIVA HandiHaler safely and effectively. See full prescribing information for SPIRIVA HandiHaler.<br><br>
	SPIRIVA<span class="Sup">®</span> HandiHaler<span class="Sup">®</span> (tiotropium bromide inhalation powder)<br>
	Capsules for Respiratory Inhalation<br><br>
	DO NOT Swallow SPIRIVA Capsules<br>
	FOR ORAL INHALATION ONLY with the HandiHaler Device<br><br>
	Initial U.S. Approval: 2004</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<a name="i852dfeb3-dc8e-448e-8006-fedbd5b05b48"></a><table border="0" width="100%">
<colgroup>
<col>
<col align="right">
</colgroup>
<tbody class="Headless">
<tr>
<td>Indications and Usage <a href="#Section_1">(1)</a>
</td>
<td align="right">12/2009</td>
</tr>
<tr>
<td>Dosage and Administration <a href="#Section_2">(2)</a>
</td>
<td align="right">12/2009</td>
</tr>
<tr>
<td>Contraindications <a href="#Section_4">(4)</a>
</td>
<td align="right">12/2009</td>
</tr>
<tr>
<td>Warnings and Precautions,</td>
<td align="right"> </td>
</tr>
<tr>
<td>          <span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">Immediate Hypersensitivity Reactions</span> <a href="#Section_5.2">(5.2)</a>
</td>
<td align="right">12/2009</td>
</tr>
<tr>
<td>          Worsening of Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> <a href="#Section_5.4">(5.4)</a>
</td>
<td align="right">12/2009</td>
</tr>
<tr>
<td>          Worsening of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span> <a href="#Section_5.5">(5.5)</a>
</td>
<td align="right">12/2009</td>
</tr>
<tr>
<td>          <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> <a href="#Section_5.6">(5.6)</a>
</td>
<td align="right">12/2009</td>
</tr>
</tbody>
</table>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">SPIRIVA HandiHaler is an
anticholinergic indicated for the long-term, once-daily, maintenance treatment
of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> associated with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>), and
for reducing <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span> <a href="#Section_1">(1)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">DO NOT swallow SPIRIVA
capsules <a href="#Section_2">(2)</a> </p>
<p class="Highlighta">For Use with the HandiHaler
Device ONLY <a href="#Section_2">(2)</a> </p>
<p class="Highlighta">For Oral Inhalation ONLY <a href="#Section_2">(2)</a> </p>
<ul class="Disc"><li>Two inhalations of the powder
contents of a single SPIRIVA capsule (18 mcg) once daily <a href="#Section_2">(2)</a>
</li></ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">SPIRIVA capsules for oral inhalation: 18 mcg tiotropium
powder, for use with HandiHaler device <a href="#Section_3">(3)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to ipratropium or tiotropium <a href="#Section_4">(4)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Not for acute use: Not for use as a
rescue medication <a href="#Section_5.1">(5.1)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">Immediate hypersensitivity</span>
reactions:  Discontinue SPIRIVA HandiHaler at once and consider alternatives if
<span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">immediate hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, occur. Use with
caution in patients with severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to milk proteins. <a href="#Section_5.2">(5.2)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">Paradoxical bronchospasm</span>: Discontinue
SPIRIVA HandiHaler and consider other treatments if <span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">paradoxical bronchospasm</span>
occurs <a href="#Section_5.3">(5.3)</a>
</li>
<li>Worsening of narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>
may occur.  Use with caution in patients with narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> and
instruct patients to consult a physician immediately if this occurs. <a href="#Section_5.4">(5.4)</a>
</li>
<li>Worsening of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> may
occur.  Use with caution in patients with <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hyperplasia</span> or bladder-neck
obstruction and instruct patients to consult a physician immediately if this
occurs. <a href="#Section_5.5">(5.5)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc"><li>
The most common adverse reactions (&gt;5% incidence in the 1-year
placebo-controlled trials) were <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>,
<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, non-specific <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, and
<span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> <a href="#Section_6.1">(6.1)</a>
</li></ul>
<p class="Highlighta">  </p>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">To report SUSPECTED ADVERSE REACTIONS, contact Boehringer
Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or (800) 459-9906 TTY, or FDA
at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Not recommended for use with other anticholinergics since
this has not been studied <a href="#Section_7.2">(7.2)</a> </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should
be monitored closely for potential anticholinergic side effects <a href="#Section_2">(2</a>, <a href="#Section_8.6">8.6)</a> </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 7/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"></a></h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION </a></h1>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  Not for Acute Use</a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Immediate <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3  Paradoxical <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4  Worsening of Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5  Worsening of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6  Renal Impairment</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1  Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2  Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1  Sympathomimetics, Methylxanthines, Steroids</a></h2>
<h2><a href="#section-7.2" class="toc">7.2  Anticholinergics</a></h2>
<h2><a href="#section-7.3" class="toc">7.3  Cimetidine, Ranitidine</a></h2>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2  Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3  Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5  Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6  Renal Impairment</a></h2>
<h2><a href="#section-8.7" class="toc">8.7  Hepatic Impairment</a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2  Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3  Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2  Animal Toxicology and Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14  CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1  Instructions for Administering SPIRIVA HandiHaler</a></h2>
<h2><a href="#section-15.2" class="toc">17.2  Paradoxical <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></a></h2>
<h2><a href="#section-15.3" class="toc">17.3  Urinary Retention</a></h2>
<h2><a href="#section-15.4" class="toc">17.4  Visual Effects</a></h2>
<h2><a href="#section-15.5" class="toc">17.5  Acute Exacerbation</a></h2>
<h2><a href="#section-15.6" class="toc">17.6  FDA-approved Patient Labeling</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">SPIRIVA HandiHaler (tiotropium bromide inhalation
powder) is indicated for the long-term, once-daily, maintenance treatment of
<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> associated with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>),
including <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> and <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>. SPIRIVA HandiHaler is indicated to
reduce exacerbations in <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> patients.</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION </h1>
<p class="First"><span class="Bold"><span class="Emphasis">DO NOT SWALLOW SPIRIVA CAPSULES<br>
FOR USE WITH HANDIHALER DEVICE ONLY</span></span></p>
<p><span class="Bold"><span class="Emphasis">FOR ORAL INHALATION ONLY</span></span></p>
<p><span class="Bold"><span class="Emphasis">SPIRIVA
capsules must not be swallowed as the intended effects on the lungs will not be
obtained. The contents of the SPIRIVA capsules are only for oral inhalation and
should only be used with the HandiHaler device </span></span>[<span class="Italics"><span class="Emphasis">see Overdosage <a href="#Section_10">(10)</a></span></span>].</p>
<p>The
recommended dose of SPIRIVA HandiHaler is two inhalations of the powder contents
of one SPIRIVA capsule, once-daily, with the HandiHaler device [<span class="Italics"><span class="Emphasis">see Patient
Counseling Information </span></span><span class="Italics"><span class="Emphasis"><a href="#Section_17.6">(17.6)</a></span></span>].</p>
<p style="border-left:1px solid;"><span class="XmChange">For administration of SPIRIVA HandiHaler, a SPIRIVA capsule
is placed into the center chamber of the HandiHaler device. The SPIRIVA capsule
is pierced by pressing and releasing the green piercing button on the side of
the HandiHaler device. The tiotropium formulation is dispersed into the air
stream when the patient inhales through the mouthpiece [<span class="Italics"><span class="Emphasis">see Patient
Counseling Information </span></span><span class="Italics"><span class="Emphasis"><a href="#Section_17.6">(17.6)</a></span></span>].</span></p>
<p>No
dosage adjustment is required for geriatric, hepatically-impaired, or
renally-impaired patients. However, patients with moderate to severe renal
impairment given SPIRIVA HandiHaler should be monitored closely for
anticholinergic effects [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.6">(5.6)</a>, Use in Specific
Populations <a href="#Section_8.5">(8.5</a>, <a href="#Section_8.6">8.6</a>, <a href="#Section_8.7">8.7)</a>, and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">SPIRIVA
HandiHaler consists of SPIRIVA capsules and a HandiHaler device. SPIRIVA
capsules contain 18 mcg dry powder formulation of tiotropium in a
light green, hard gelatin capsule with TI 01 printed on one side and Boehringer
Ingelheim company logo on the other side. Supplied with a HandiHaler device.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">SPIRIVA HandiHaler
is contraindicated in patients with a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>
to ipratropium or tiotropium.  In clinical trials and postmarketing experience
with SPIRIVA HandiHaler, <span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">immediate hypersensitivity reactions</span>, including
<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (including <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the lips, tongue, or throat), <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> have been reported.</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1  Not for Acute Use</h2>
<p class="First">SPIRIVA
HandiHaler is intended as a once-daily maintenance treatment for <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> and is
not indicated for the initial treatment of acute episodes of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> (i.e.,
rescue therapy).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2  Immediate <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">Immediate hypersensitivity reactions</span>, including
<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (including <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the lips, tongue, or throat), <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> may occur after administration of SPIRIVA HandiHaler. If such a reaction
occurs, therapy with SPIRIVA HandiHaler should be stopped at once and
alternative treatments should be considered. Given the similar structural
formula of atropine to tiotropium, patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>
reactions to atropine should be closely monitored for similar <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>
reactions to SPIRIVA HandiHaler.  In addition, SPIRIVA HandiHaler should be
used with caution in patients with severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to milk proteins.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3  Paradoxical <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></h2>
<p class="First">Inhaled
medicines, including SPIRIVA HandiHaler, may cause <span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">paradoxical bronchospasm</span>. If
this occurs, treatment with SPIRIVA HandiHaler should be stopped and other
treatments considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4  Worsening of Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">SPIRIVA HandiHaler should be used with caution in
patients with narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.  Prescribers and patients should be alert
for signs and symptoms of acute narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> (e.g., <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span> or
<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, visual halos or colored images in association with
<span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eyes</span> from <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival congestion</span> and <span class="product-label-link" type="condition" conceptid="377875" conceptname="Idiopathic corneal edema">corneal edema</span>). Instruct patients to
consult a physician immediately should any of these signs or symptoms develop.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5  Worsening of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">SPIRIVA HandiHaler should be used with caution in
patients with <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>.  Prescribers and patients should be alert for
signs and symptoms of <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hyperplasia</span> or bladder-neck obstruction (e.g.,
difficulty passing urine, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">painful urination</span>).  Instruct patients to consult a physician
immediately should any of these signs or symptoms develop.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6  Renal Impairment</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">As
a predominantly renally excreted drug, patients with moderate to severe renal
impairment (creatinine clearance of ≤50 mL/min) treated
with SPIRIVA HandiHaler should be monitored closely for anticholinergic side
effects [<span class="Italics"><span class="Emphasis">see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span></span>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<p class="First">The following adverse
reactions are described, or described in greater detail, in other sections:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">Immediate hypersensitivity</span>
reactions [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.2">(5.2)</a></span></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">Paradoxical bronchospasm</span> [<span class="Italics"><span class="Emphasis">see
Warnings and Precautions <a href="#Section_5.3">(5.3)</a></span></span>]</li>
<li>Worsening of narrow-angle
<span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_">(5.4)</a></span></span>]</li>
<li>Worsening of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> [<span class="Italics"><span class="Emphasis">see
Warnings and Precautions <a href="#Section_5.5">(5.5)</a></span></span>]</li>
</ul>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1  Clinical Trials Experience</h2>
<p class="First">Because clinical trials
are conducted under widely varying conditions, adverse reaction rates observed
in the clinical trials of a drug cannot be directly compared to rates in the
clinical trials of another drug and may not reflect the rates observed in
practice.</p>
<p><span class="Italics"><span class="Emphasis">6-Month to 1-Year Trials</span></span></p>
<p>The
data described below reflect exposure to SPIRIVA HandiHaler in 2663 patients. 
SPIRIVA HandiHaler was studied in two 1-year placebo-controlled trials, two
1-year active-controlled trials, and two 6-month placebo-controlled trials in
patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>. In these trials, 1308 patients
were treated with SPIRIVA HandiHaler at the recommended dose of 18 mcg
once a day.  The population had an age ranging from 39 to 87 years with 65% to
85% males, 95% Caucasian, and had <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> with a mean pre-bronchodilator forced
expiratory volume in one second (FEV<span class="Sub">1</span>) percent predicted of 39% to 43%.  Patients with narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, or
symptomatic <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or bladder outlet obstruction were excluded
from these trials.  An additional 6-month trial conducted in a Veteran's
Affairs setting is not included in this safety database because only serious
adverse events were collected.</p>
<p>The
most commonly reported adverse drug reaction was <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>. <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span> was
usually mild and often resolved during continued treatment. Other reactions
reported in individual patients and consistent with possible anticholinergic
effects included <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> (new onset
or worsening), <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>.</p>
<p>Four
multicenter, 1-year, placebo-controlled and active-controlled trials evaluated
SPIRIVA HandiHaler in patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>. Table 1 shows all adverse reactions
that occurred with a frequency of ≥3% in the SPIRIVA HandiHaler
group in the 1-year placebo-controlled trials where the rates in the SPIRIVA HandiHaler
group exceeded placebo by ≥1%.  The frequency of corresponding reactions in the
ipratropium-controlled trials is included for comparison.</p>
<p><span class="Bold"><span class="Emphasis">Table 1    Adverse Reactions
(% Patients) in One-Year <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> Clinical Trials</span></span></p>
<a name="i84c24d92-0da0-4218-8817-d6a56d5bf7d7"></a><table border="0" cellpadding="0" cellspacing="0" width="90%">
<thead>
<tr class="First">
<th align="left">Body System (Event)</th>
<th align="left" colspan="2">Placebo-Controlled Trials</th>
<th align="left" colspan="2">Ipratropium-Controlled Trials</th>
</tr>
<tr class="Last">
<th class="Botrule" align="center"> </th>
<th class="Botrule" align="left">SPIRIVA<br>(n = 550)</th>
<th class="Botrule" align="left">Placebo<br>(n = 371)</th>
<th class="Botrule" align="left">SPIRIVA<br>(n = 356)</th>
<th class="Botrule" align="left">Ipratropium<br>(n = 179)</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule" align="left">
<span class="Bold">Body as a Whole</span><br><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span> (non-specific)</td>
<td class="Botrule" align="left" valign="bottom">7</td>
<td class="Botrule" align="left" valign="bottom">5</td>
<td class="Botrule" align="left" valign="bottom">5</td>
<td class="Botrule" align="left" valign="bottom">2</td>
</tr>
<tr>
<td class="Botrule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, Dependent</td>
<td class="Botrule" align="left">5</td>
<td class="Botrule" align="left">4</td>
<td class="Botrule" align="left">3</td>
<td class="Botrule" align="left">5</td>
</tr>
<tr>
<td class="Botrule" align="left">
<span class="Bold">Gastrointestinal System Disorders</span><br><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td class="Botrule" align="left" valign="bottom">16</td>
<td class="Botrule" align="left" valign="bottom">3</td>
<td class="Botrule" align="left" valign="bottom">12</td>
<td class="Botrule" align="left" valign="bottom">6</td>
</tr>
<tr>
<td class="Botrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Botrule" align="left">6</td>
<td class="Botrule" align="left">5</td>
<td class="Botrule" align="left">1</td>
<td class="Botrule" align="left">1</td>
</tr>
<tr>
<td class="Botrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Botrule" align="left">5</td>
<td class="Botrule" align="left">3</td>
<td class="Botrule" align="left">6</td>
<td class="Botrule" align="left">6</td>
</tr>
<tr>
<td class="Botrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Botrule" align="left">4</td>
<td class="Botrule" align="left">2</td>
<td class="Botrule" align="left">1</td>
<td class="Botrule" align="left">1</td>
</tr>
<tr>
<td class="Botrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule" align="left">4</td>
<td class="Botrule" align="left">2</td>
<td class="Botrule" align="left">1</td>
<td class="Botrule" align="left">2</td>
</tr>
<tr>
<td class="Botrule" align="left">
<span class="Bold">Musculoskeletal System</span><br><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Botrule" align="left" valign="bottom">4</td>
<td class="Botrule" align="left" valign="bottom">3</td>
<td class="Botrule" align="left" valign="bottom">4</td>
<td class="Botrule" align="left" valign="bottom">3</td>
</tr>
<tr>
<td class="Botrule" align="left">
<span class="Bold">Resistance Mechanism Disorders</span><br><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Botrule" align="left" valign="bottom">4</td>
<td class="Botrule" align="left" valign="bottom">3</td>
<td class="Botrule" align="left" valign="bottom">1</td>
<td class="Botrule" align="left" valign="bottom">3</td>
</tr>
<tr>
<td class="Botrule" align="left"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Moniliasis</span></td>
<td class="Botrule" align="left">4</td>
<td class="Botrule" align="left">2</td>
<td class="Botrule" align="left">3</td>
<td class="Botrule" align="left">2</td>
</tr>
<tr>
<td class="Botrule" align="left">
<span class="Bold">Respiratory System (Upper)</span><br><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></td>
<td class="Botrule" align="left" valign="bottom">41</td>
<td class="Botrule" align="left" valign="bottom">37</td>
<td class="Botrule" align="left" valign="bottom">43</td>
<td class="Botrule" align="left" valign="bottom">35</td>
</tr>
<tr>
<td class="Botrule" align="left"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Botrule" align="left">11</td>
<td class="Botrule" align="left">9</td>
<td class="Botrule" align="left">3</td>
<td class="Botrule" align="left">2</td>
</tr>
<tr>
<td class="Botrule" align="left"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td class="Botrule" align="left">9</td>
<td class="Botrule" align="left">7</td>
<td class="Botrule" align="left">7</td>
<td class="Botrule" align="left">3</td>
</tr>
<tr>
<td class="Botrule" align="left"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td class="Botrule" align="left">6</td>
<td class="Botrule" align="left">5</td>
<td class="Botrule" align="left">3</td>
<td class="Botrule" align="left">2</td>
</tr>
<tr>
<td class="Botrule" align="left"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Botrule" align="left">4</td>
<td class="Botrule" align="left">2</td>
<td class="Botrule" align="left">1</td>
<td class="Botrule" align="left">1</td>
</tr>
<tr>
<td class="Botrule" align="left">
<span class="Bold">Skin and Appendage Disorders</span><br><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule" align="left" valign="bottom">4</td>
<td class="Botrule" align="left" valign="bottom">2</td>
<td class="Botrule" align="left" valign="bottom">2</td>
<td class="Botrule" align="left" valign="bottom">2</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left">
<span class="Bold">Urinary System</span><br><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span></td>
<td class="Botrule" align="left" valign="bottom">7</td>
<td class="Botrule" align="left" valign="bottom">5</td>
<td class="Botrule" align="left" valign="bottom">4</td>
<td class="Botrule" align="left" valign="bottom">2</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span>,
<span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, and <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms occurred at a rate of ≥3% in the
SPIRIVA HandiHaler treatment group, but were &lt;1% in excess
of the placebo group.</p>
<p>Other reactions that
occurred in the SPIRIVA HandiHaler group at a frequency of 1% to 3% in the
placebo-controlled trials where the rates exceeded that in the placebo group
include: <span class="Italics"><span class="Emphasis">Body as a Whole:</span></span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span>; <span class="Italics"><span class="Emphasis">Central and Peripheral Nervous System:</span></span> <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>; <span class="Italics"><span class="Emphasis">Gastrointestinal System Disorders:</span></span> <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorder</span> not otherwise specified (NOS),
<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> (including <span class="product-label-link" type="condition" conceptid="4160872" conceptname="Recurrent aphthous ulcer">ulcerative stomatitis</span>); <span class="Italics"><span class="Emphasis">Metabolic and Nutritional Disorders:</span></span> <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>; <span class="Italics"><span class="Emphasis">Musculoskeletal System Disorders:</span></span> <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">skeletal pain</span>; <span class="Italics"><span class="Emphasis">Cardiac Events:</span></span> <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> (including aggravated <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>); <span class="Italics"><span class="Emphasis">Psychiatric Disorder:</span></span> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>;
<span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>:</span></span> <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>; <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorder</span> (Upper):</span></span>
<span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>; <span class="Italics"><span class="Emphasis">Vision Disorder:</span></span> <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>.  In addition, among the adverse reactions
observed in the clinical trials with an incidence of &lt;1% were <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>.</p>
<p>In the 1-year trials,
the incidence of <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> increased
with age [<span class="Italics"><span class="Emphasis">see Use in Specific Populations <a href="#Section_8.5">(8.5)</a></span></span>].</p>
<p>Two multicenter, 6-month,
controlled studies evaluated SPIRIVA HandiHaler in patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>. The
adverse reactions and the incidence rates were similar to those seen in the
1-year controlled trials.</p>
<p><span class="Italics"><span class="Emphasis">4-Year Trial</span></span><br>
The data described below reflect exposure to SPIRIVA
HandiHaler in 5992 <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> patients in a 4-year placebo-controlled trial.  In this
trial, 2986 patients were treated with SPIRIVA HandiHaler at the recommended
dose of 18 mcg once a day. The population had an age range from 40 to 88
years, was 75% male, 90% Caucasian, and had <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> with a mean pre-bronchodilator
FEV<span class="Sub">1</span> percent predicted of 40%. Patients with narrow-angle
<span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, or symptomatic <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or bladder outlet obstruction
were excluded from these trials.  When the adverse reactions were analyzed with
a frequency of ≥3% in the SPIRIVA HandiHaler group where the rates in the
SPIRIVA HandiHaler group exceeded placebo by ≥1%, adverse reactions included (SPIRIVA HandiHaler, placebo): <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> (12.5%, 10.8%), <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> (6.5%, 5.3%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (5.7%, 4.5%), <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (5.1%, 3.7%), <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> (5.1%, 2.7%), <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (4.4%, 3.3%), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (4.4%, 3.0%), and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (4.2%, 3.1%).</p>
<p><span class="Italics"><span class="Emphasis">Additional
Adverse Reactions</span></span><br>
Other adverse reactions not previously listed that were reported more frequently in
<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> patients treated with SPIRIVA HandiHaler than placebo include: 
<span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulcer</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>, <span class="product-label-link" type="condition" conceptid="4080451" conceptname="Pharyngeal candidiasis">oropharyngeal candidiasis</span>, dry
skin, <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infection</span>, and <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2  Postmarketing Experience</h2>
<p class="First">Adverse
reactions have been identified during worldwide post-approval use of SPIRIVA
HandiHaler. Because these reactions are reported voluntarily from a population
of uncertain size, it is not always possible to reliably estimate their
frequency or establish a causal relationship to drug exposure.  These adverse
reactions are: <span class="product-label-link" type="condition" conceptid="4318383" conceptname="Application site irritation">application site irritation</span> (<span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>, and
pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>, intestinal
obstruction including <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">ileus paralytic</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">intraocular pressure increased</span>, oral
<span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span>, and
<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1  Sympathomimetics, Methylxanthines, Steroids</h2>
<p class="First">SPIRIVA
HandiHaler has been used concomitantly with short-acting and long-acting sympathomimetic
(beta-agonists) bronchodilators, methylxanthines, and oral and inhaled steroids
without increases in adverse drug reactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2  Anticholinergics</h2>
<p class="First">The
co-administration of SPIRIVA HandiHaler with other anticholinergic-containing
drugs (e.g., ipratropium) has not been studied and is therefore not
recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3  Cimetidine, Ranitidine</h2>
<p class="First">No
clinically significant interaction occurred between tiotropium and cimetidine
or ranitidine [<span class="Italics"><span class="Emphasis">see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="First"><span class="Italics"><span class="Emphasis">Teratogenic
Effects, Pregnancy Category C.</span></span><br>
There are no adequate and well-controlled studies in pregnant women.  SPIRIVA
HandiHaler should be used during pregnancy only if the potential benefit
justifies the potential risk to the fetus.</p>
<p>No
evidence of structural alterations was observed in rats and rabbits at
inhalation tiotropium doses of up to approximately 660 and 6 times the
recommended human daily inhalation dose (RHDID) on a mg/m<span class="Sup">2</span> basis,
respectively. However, in rats, tiotropium caused fetal resorption, litter loss,
decreases in the number of live pups at birth and the mean pup weights, and a
delay in pup sexual maturation at inhalation tiotropium doses of approximately
35 times the RHDID on a mg/m<span class="Sup">2</span> basis. In rabbits, tiotropium caused an
increase in post-implantation loss at an inhalation dose of approximately 360
times the RHDID on a mg/m<span class="Sup">2</span> basis. Such effects were not observed at
inhalation doses of approximately 4 and 80 times the RHDID on a mg/m<span class="Sup">2</span>
basis, respectively. These dose multiples may be over-estimated due to
difficulties in measuring deposited doses in animal inhalation studies.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="Section_8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2  Labor and Delivery</h2>
<p class="First">The
safety and effectiveness of SPIRIVA HandiHaler has not been studied during
labor and delivery.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3  Nursing Mothers</h2>
<p class="First">Clinical
data from nursing women exposed to tiotropium are not available. Based on
lactating rodent studies, tiotropium is excreted into breast milk. It is not
known whether tiotropium is excreted in human milk, but because many drugs are
excreted in human milk and given these findings in rats, caution should be
exercised if SPIRIVA HandiHaler is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First">SPIRIVA
HandiHaler is approved for use in the maintenance treatment of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>
associated with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> and for the reduction of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span>. <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> does not
normally occur in children. The safety and effectiveness of SPIRIVA HandiHaler in
pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First">Of
the total number of patients who received SPIRIVA HandiHaler in the 1-year
clinical trials, 426 were &lt;65 years, 375 were 65 to 74 years, and
105 were ≥75 years of age. Within each age subgroup, there were
no differences between the proportion of patients with adverse events in the
SPIRIVA HandiHaler and the comparator groups for most events. <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>
increased with age in the SPIRIVA HandiHaler group (differences from placebo
were 9.0%, 17.1%, and 16.2% in the aforementioned age subgroups). A higher
frequency of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> with increasing age was
observed in the SPIRIVA HandiHaler group in the placebo-controlled studies. The
differences from placebo for <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> were 0%, 1.8%, and 7.8% for each of
the age groups. The differences from placebo for <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> were
–0.6%, 4.6%, and 4.5%. No overall differences in effectiveness were observed
among these groups. Based on available data, no adjustment of SPIRIVA HandiHaler
dosage in geriatric patients is warranted [<span class="Italics"><span class="Emphasis">see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6  Renal Impairment</h2>
<p class="First">Patients
with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance of ≤50
mL/min) treated with SPIRIVA HandiHaler should be monitored closely for
anticholinergic side effects [<span class="Italics"><span class="Emphasis">see Dosage and Administration <a href="#Section_2">(2)</a>, Warnings
and Precautions <a href="#Section_5.4">(5.4)</a>, and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.7"></a><a name="section-8.7"></a><p></p>
<h2>8.7  Hepatic Impairment</h2>
<p class="First">The
effects of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of tiotropium were not
studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First">High
doses of tiotropium may lead to anticholinergic signs and symptoms. However,
there were no systemic anticholinergic adverse effects following a single
inhaled dose of up to 282 mcg tiotropium in 6 healthy volunteers. In a study of
12 healthy volunteers, bilateral <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> were seen
following repeated once-daily inhalation of 141 mcg of tiotropium.</p>
<p><span class="Italics"><span class="Emphasis">Accidental Ingestion</span></span><br><span class="Bold"><span class="Emphasis">Acute <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>
by inadvertent oral ingestion of SPIRIVA capsules is unlikely since it is not
well-absorbed systemically.</span></span></p>
<p>A
case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> has been reported from postmarketing experience. A female
patient was reported to have inhaled 30 capsules over a 2.5 day period, and
developed altered mental status, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and severe
<span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. The patient was hospitalized, SPIRIVA HandiHaler was
discontinued, and the <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> was treated with an enema. The patient
recovered and was discharged on the same day.</p>
<p>No
mortality was observed at inhalation tiotropium doses up to 32.4 mg/kg in mice,
267.7 mg/kg in rats, and 0.6 mg/kg in dogs. These doses correspond to 7300,
120,000, and 850 times the recommended human daily inhalation dose on a mg/m<span class="Sup">2</span>
basis, respectively. These dose multiples may be over-estimated due to
difficulties in measuring deposited doses in animal inhalation studies.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">SPIRIVA
HandiHaler consists of a capsule dosage form containing a dry powder
formulation of tiotropium intended for oral inhalation only with the HandiHaler
device.</p>
<p>Each
light green, hard gelatin SPIRIVA capsule contains 18 mcg tiotropium
(equivalent to 22.5 mcg tiotropium bromide monohydrate) blended with
lactose monohydrate (which may contain milk proteins) as the carrier.</p>
<p>The
dry powder formulation within the SPIRIVA capsule is intended for oral
inhalation only.</p>
<p>The
active component of SPIRIVA HandiHaler is tiotropium. The drug substance,
tiotropium bromide monohydrate, is an anticholinergic with specificity for
muscarinic receptors. It is chemically described as (1α,
2ß, 4ß, 5α,
7ß)-7-[(Hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0<span class="Sup">2,4</span>]nonane
bromide monohydrate. It is a synthetic, non-chiral, quaternary ammonium
compound. Tiotropium bromide is a white or yellowish white powder. It is
sparingly soluble in water and soluble in methanol.</p>
<p>The
structural formula is:</p>
<div class="Figure"><img alt="SPIRIVA Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Structure1.jpg"></div>
<br><p>Tiotropium
bromide (monohydrate) has a molecular <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> of 490.4 and a molecular formula of
C<span class="Sub">19</span>H<span class="Sub">22</span>NO<span class="Sub">4</span>S<span class="Sub">2</span>Br • H<span class="Sub">2</span>O.</p>
<p>The HandiHaler device is an inhalation device used to inhale the dry powder
contained in the SPIRIVA capsule. The dry powder is delivered from the
HandiHaler device at flow rates as low as 20 L/min. Under standardized <span class="Italics"><span class="Emphasis">in
vitro</span></span> testing, the HandiHaler device delivers a mean of 10.4 mcg
tiotropium when tested at a flow rate of 39 L/min for 3.1 seconds (2 L total).
In a study of 26 adult patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> and severely compromised lung
function [mean FEV<span class="Sub">1</span> 1.02 L (range 0.45 to 2.24 L); 37.6% of
predicted (range 16% to 65%)], the median peak inspiratory flow (PIF) through
the HandiHaler device was 30.0 L/min (range 20.4 to 45.6 L/min). The amount of
drug delivered to the lungs will vary depending on patient factors such as
inspiratory flow and peak inspiratory flow through the HandiHaler device, which
may vary from patient to patient, and may vary with the exposure time of the SPIRIVA
capsule outside the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">Tiotropium
is a long-acting, antimuscarinic agent, which is often referred to as an
anticholinergic. It has similar affinity to the subtypes of muscarinic
receptors, M<span class="Sub">1</span> to M<span class="Sub">5</span>.  In the airways, it exhibits
pharmacological effects through inhibition of M<span class="Sub">3</span>-receptors at the
smooth muscle leading to bronchodilation. The competitive and reversible nature
of antagonism was shown with human and animal origin receptors and isolated
organ preparations. In preclinical <span class="Italics"><span class="Emphasis">in vitro</span></span> as well as <span class="Italics"><span class="Emphasis">in vivo</span></span>
studies, prevention of methacholine-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> effects was
dose-dependent and lasted longer than 24 hours. The bronchodilation following
inhalation of tiotropium is predominantly a site-specific effect.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="Section_12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2  Pharmacodynamics</h2>
<p class="First"><span class="Italics"><span class="Emphasis">Cardiovascular
Effects</span></span><br>
In a multicenter, randomized, double-blind trial that enrolled 198 patients with
<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>, the number of subjects with changes from baseline-corrected QT interval
of 30 to 60 msec was higher in the SPIRIVA HandiHaler group as compared with
placebo. This difference was apparent using both the Bazett (QTcB) [20 (20%)
patients vs 12 (12%) patients] and Fredericia (QTcF) [16 (16%) patients vs 1 (1%) patient] corrections of QT for heart rate. No patients in either group had
either QTcB or QTcF of &gt;500 msec. Other clinical studies with SPIRIVA
HandiHaler did not detect an effect of the drug on QTc intervals. </p>
<p>The
effect of SPIRIVA HandiHaler on QT interval was also evaluated in a randomized,
placebo- and positive-controlled crossover study in 53 healthy volunteers.
Subjects received SPIRIVA HandiHaler 18 mcg, 54 mcg (3 times the recommended
dose), or placebo for 12 days. ECG assessments were performed at baseline and
throughout the dosing interval following the first and last dose of study
medication. Relative to placebo, the maximum mean change from baseline in
study-specific QTc interval was 3.2 msec and 0.8 msec for SPIRIVA HandiHaler 18
mcg and 54 mcg, respectively. No subject showed a new onset of QTc &gt;500 msec
or QTc changes from baseline of ≥60 msec.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First">Tiotropium
is administered by dry powder inhalation. In common with other inhaled drugs,
the majority of the delivered dose is deposited in the gastrointestinal tract
and, to a lesser extent, in the lung, the intended organ. Many of the
pharmacokinetic data described below were obtained with higher doses than
recommended for therapy.</p>
<p><span class="Italics"><span class="Emphasis">Absorption</span></span><br>
Following dry powder inhalation by young healthy volunteers, the absolute bioavailability
of 19.5% suggests that the fraction reaching the lung is highly bioavailable.
It is expected from the chemical structure of the compound (quaternary ammonium
compound) that tiotropium is poorly absorbed from the gastrointestinal tract. The
effect of food on tiotropium's bioavailability has not been studied.  Oral
solutions of tiotropium have an absolute bioavailability of 2% to 3%.
Maximum tiotropium plasma concentrations were observed 5 minutes after
inhalation.</p>
<p><span class="Italics"><span class="Emphasis">Distribution</span></span><br>
Tiotropium shows a volume of distribution of 32 L/kg indicating that the drug binds
extensively to tissues. The human plasma protein binding for tiotropium is 72%.
At steady state, peak tiotropium plasma levels in <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> patients were 17 to 19
pg/mL when measured 5 minutes after dry powder inhalation of an 18 mcg dose and
decreased in a multi-compartmental manner. Steady-state trough plasma
concentrations were 3 to 4 pg/mL. Local concentrations in the lung
are not known, but the mode of administration suggests substantially higher
concentrations in the lung. Studies in rats have shown that tiotropium does not
readily penetrate the blood-brain barrier.</p>
<p><span class="Italics"><span class="Emphasis">Metabolism</span></span><br>
The extent of metabolism appears to be small. This is evident from a urinary
excretion of 74% of unchanged substance after an intravenous dose to young
healthy volunteers. Tiotropium, an ester, is nonenzymatically cleaved to the
alcohol <span class="Italics"><span class="Emphasis">N</span></span>-methylscopine and dithienylglycolic acid, neither of which
bind to muscarinic receptors.</p>
<p><span class="Italics"><span class="Emphasis">In
vitro</span></span> experiments with human liver
microsomes and human hepatocytes suggest that a fraction of the administered
dose (74% of an intravenous dose is excreted unchanged in the urine, leaving
25% for metabolism) is metabolized by cytochrome P450-dependent oxidation and
subsequent glutathione conjugation to a variety of Phase II metabolites. This
enzymatic pathway can be inhibited by CYP450 2D6 and 3A4 inhibitors, such as
quinidine, ketoconazole, and gestodene. Thus, CYP450 2D6 and 3A4 are involved
in the metabolic pathway that is responsible for the elimination of a small
part of the administered dose. <span class="Italics"><span class="Emphasis">In vitro</span></span> studies using human liver
microsomes showed that tiotropium in supra-therapeutic concentrations did not
inhibit CYP450 1A1, 1A2, 2B6, 2C9, 2C19, 2D6, 2E1, or 3A4.</p>
<p><span class="Italics"><span class="Emphasis">Elimination</span></span><br>
The terminal elimination half-life of tiotropium was between 5 and 6 days following
inhalation. Total clearance was 880 mL/min after an intravenous dose in young
healthy volunteers with an inter-individual variability of 22%. Intravenously
administered tiotropium was mainly excreted unchanged in urine (74%). After dry
powder inhalation, urinary excretion was 14% of the dose, the remainder being
mainly non-absorbed drug in the gut which was eliminated via the feces. The
renal clearance of tiotropium exceeds the creatinine clearance, indicating
active secretion into the urine. After chronic once-daily inhalation by <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>
patients, pharmacokinetic steady state was reached after 2 to 3 weeks
with no accumulation thereafter.</p>
<p><span class="Italics"><span class="Emphasis">Drug Interactions</span></span><br>
An interaction study with tiotropium (14.4 mcg intravenous infusion over 15
minutes) and cimetidine 400 mg three times daily or ranitidine 300 mg once
daily was conducted. Concomitant administration of cimetidine with tiotropium
resulted in a 20% increase in the AUC<span class="Sub">0-4h</span>, a 28% decrease in the
renal clearance of tiotropium and no significant change in the C<span class="Sub">max</span>
and amount excreted in urine over 96 hours. Co-administration of tiotropium
with ranitidine did not affect the pharmacokinetics of tiotropium.</p>
<p><span class="Italics"><span class="Emphasis">Specific
Populations</span></span><br><span class="Underline">Geriatric
Patients</span><br>
As expected for drugs predominantly excreted renally, advanced age was associated
with a decrease of tiotropium renal clearance (326 mL/min in <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> patients
&lt;58 years to 163 mL/min in <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> patients &gt;70 years), which may be
explained by decreased renal function. Tiotropium excretion in urine after
inhalation decreased from 14% (young healthy volunteers) to about 7% (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>
patients). Plasma concentrations were numerically increased with advancing age
within <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> patients (43% increase in AUC<span class="Sub">0-4</span> after dry powder
inhalation), which was not significant when considered in relation to inter-
and intra-individual variability [<span class="Italics"><span class="Emphasis">see</span></span><span class="Italics"><span class="Emphasis">Dosage and Administration <a href="#Section_2">(2)</a> and
Use in Specific Populations <a href="#Section_8.5">(8.5)</a></span></span>].</p>
<p><span class="Underline">Renal
Impairment</span><br>
Since tiotropium is predominantly renally excreted, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> was associated
with increased plasma drug concentrations and reduced drug clearance after both
intravenous infusion and dry powder inhalation. Mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine
clearance of 50 to 80 mL/min), which is often seen in elderly patients,
increased tiotropium plasma concentrations (39% increase in AUC<span class="Sub">0-4 </span>after
intravenous infusion). In <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> patients with moderate to severe renal
impairment (creatinine clearance of &lt;50 mL/min), the intravenous
administration of tiotropium resulted in doubling of the plasma concentrations
(82% increase in AUC<span class="Sub">0-4</span>), which was confirmed by plasma
concentrations after dry powder inhalation.  Patients with moderate to severe
<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance of ≤50 mL/min) treated with
SPIRIVA HandiHaler should be monitored closely for anticholinergic side effects
[<span class="Italics"><span class="Emphasis">see Dosage and Administration <a href="#Section_2">(2)</a>,<span class="Bold"><span class="Emphasis"></span></span>Warnings and Precautions <a href="#Section_5.4">(5.4)</a>,
and Use in Specific Populations <a href="#Section_8.6">(8.6)</a></span></span>].</p>
<p><span class="Underline">Hepatic
Impairment</span><br>
The effects of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of tiotropium were not
studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No
evidence of tumorigenicity was observed in a 104-week inhalation study in rats
at tiotropium doses up to 0.059 mg/kg/day, in an 83-week inhalation study in
female mice at doses up to 0.145 mg/kg/day, and in a 101-week inhalation
study in male mice at doses up to 0.002 mg/kg/day. These doses correspond to approximately
25, 35, and 0.5 times the recommended human daily inhalation dose (RHDID) on a
mg/m<span class="Sup">2</span> basis, respectively. These dose multiples may be
over-estimated due to difficulties in measuring deposited doses in animal
inhalation studies.</p>
<p>Tiotropium bromide demonstrated no evidence of mutagenicity or clastogenicity in the
following assays: the bacterial gene mutation assay, the V79 Chinese hamster
cell mutagenesis assay, the chromosomal aberration assays in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> <span class="Italics"><span class="Emphasis">in
vitro</span></span> and mouse micronucleus formation <span class="Italics"><span class="Emphasis">in vivo</span></span>, and the unscheduled
DNA synthesis in primary rat hepatocytes <span class="Italics"><span class="Emphasis">in vitro</span></span> assay.</p>
<p>In rats, decreases in the number of corpora lutea and the percentage of implants
were noted at inhalation tiotropium doses of 0.078 mg/kg/day or greater
(approximately 35 times the RHDID on a mg/m<span class="Sup">2 </span>basis). No such
effects were observed at 0.009 mg/kg/day (approximately 4 times than the
RHDID on a mg/m<span class="Sup">2</span> basis). The fertility index, however, was not
affected at inhalation doses up to 1.689 mg/kg/day (approximately 760 times the
RHDID on a mg/m<span class="Sup">2</span> basis). These dose multiples may be over-estimated
due to difficulties in measuring deposited doses in animal inhalation studies.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="Section_13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2  Animal Toxicology and Pharmacology</h2>
<p class="First"><span class="Italics"><span class="Emphasis">Reproductive
Toxicology Studies</span></span><br>
No evidence of fetal structural alteration was observed in rats and rabbits at
inhalation tiotropium doses of up to 1.471 and 0.007 mg/kg/day, respectively.
These doses correspond to approximately 660 and 6 times the RHDID on a mg/m<span class="Sup">2</span> basis, respectively. However, in rats, fetal
resorption, litter loss, decreases in the number of live pups at birth and the
mean pup weights, and a delay in pup sexual maturation were observed at
inhalation tiotropium doses of ≥0.078 mg/kg (approximately 35 times the
RHDID on a mg/m<span class="Sup">2</span> basis). In rabbits, an increase in post-implantation
loss was observed at an inhalation dose of 0.4 mg/kg/day (approximately 360
times the RHDID on a mg/m<span class="Sup">2</span> basis).
Such effects were not observed at inhalation doses of 0.009 and up to 0.088
mg/kg/day in rats and rabbits, respectively. These doses correspond to
approximately 4 and 80 times the RHDID on a mg/m<span class="Sup">2</span> basis, respectively. These dose multiples may be
over-estimated due to difficulties in measuring deposited doses in animal
inhalation studies.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<p class="First">The
SPIRIVA HandiHaler (tiotropium bromide inhalation powder) clinical development
program consisted of six Phase 3 studies in 2663 patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> (1308
receiving SPIRIVA HandiHaler): two 1-year, placebo‑controlled studies,
two 6-month, placebo-controlled studies and two 1-year, ipratropium-controlled
studies. These studies enrolled patients who had a clinical diagnosis of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>,
were 40 years of age or older, had a history of smoking greater than 10
pack-years, had a forced expiratory volume in one second (FEV<span class="Sub">1</span>) less
than or equal to 60% or 65% of predicted, and a ratio of FEV<span class="Sub">1</span>/FVC of
less than or equal to 0.7.</p>
<p>In these studies, SPIRIVA HandiHaler, administered once-daily in the morning,
provided improvement in lung function (FEV<span class="Sub">1</span>), with peak effect
occurring within 3 hours following the first dose.</p>
<p>Two additional trials
evaluated exacerbations: a 6-month, randomized, double-blind,
placebo-controlled, multicenter clinical trial of 1829 <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> patients in a US
Veterans Affairs setting and a 4-year, randomized, double-blind,
placebo-controlled, multicenter, clinical trial of 5992 <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> patients. 
Long-term effects on lung function and other outcomes were also evaluated in
the 4-year multicenter trial.</p>
<p><span class="Italics"><span class="Emphasis">6-Month to 1-Year
Effects on Lung Function</span></span><br>
In the 1-year, placebo-controlled trials, the mean improvement in FEV<span class="Sub">1 </span>at
30 minutes was 0.13 liters (13%) with a peak improvement of 0.24 liters
(24%) relative to baseline after the first dose (Day 1). Further improvements
in FEV<span class="Sub">1</span> and forced <span class="product-label-link" type="condition" conceptid="4147814" conceptname="Vital capacity">vital capacity</span> (FVC) were observed with
pharmacodynamic steady state reached by Day 8 with once-daily treatment. The
mean peak improvement in FEV<span class="Sub">1</span>, relative to baseline, was 0.28 to
0.31 liters (28% to 31%), after 1 week (Day 8) of once-daily treatment. Improvement
of lung function was maintained for 24 hours after a single dose and
consistently maintained over the 1-year treatment period with no evidence of
tolerance.</p>
<p>In the two 6-month, placebo-controlled trials, serial spirometric evaluations were
performed throughout daytime hours in Trial A (12 hours) and limited to 3 hours
in Trial B. The serial FEV<span class="Sub">1</span> values over 12 hours (Trial A)
are displayed in Figure 1. These trials further support the improvement in
pulmonary function (FEV<span class="Sub">1</span>) with SPIRIVA HandiHaler, which persisted
over the spirometric observational period. Effectiveness was maintained for 24
hours after administration over the 6-month treatment period.</p>
<p><span class="Bold"><span class="Emphasis">Figure 1 Mean FEV<span class="Sub">1</span> Over Time (prior to
and after administration of study drug) on Days 1 and 169 for Trial A (a Six-Month Placebo-Controlled Study)*</span></span></p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Figure1.jpg"></div>
<p>*Means
adjusted for center, treatment, and baseline effect. On Day 169, a total of 183
and 149 patients in the SPIRIVA HandiHaler and placebo groups, respectively,
completed the trial. The data for the remaining patients were imputed using the
last observation or least favorable observation carried forward.</p>
<p>Results
of each of the 1-year ipratropium-controlled trials were similar to the results
of the 1-year placebo-controlled trials. The results of one of these trials are
shown in Figure 2.</p>
<p><span class="Bold"><span class="Emphasis">Figure 2  Mean FEV<span class="Sub">1</span> Over Time
(0 to 6 hours post-dose) on Days 1 and 92, Respectively for One of the Two
Ipratropium-Controlled Studies*</span></span></p>
<div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Figure2.jpg"></div>
<p>*Means
adjusted for center, treatment, and baseline effect. On Day 92 (primary
endpoint), a total of 151 and 69 patients in the SPIRIVA HandiHaler and
ipratropium groups, respectively, completed through 3 months of observation.
The data for the remaining patients were imputed using the last observation or
least favorable observation carried forward.</p>
<p>A randomized, placebo-controlled clinical study in 105 patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>
demonstrated that bronchodilation was maintained throughout the 24-hour dosing
interval in comparison to placebo, regardless of whether SPIRIVA HandiHaler was
administered in the morning or in the evening.</p>
<p>Throughout each week of the one-year treatment period in the two placebo-controlled
trials, patients taking SPIRIVA HandiHaler had a reduced requirement for the
use of rescue short-acting beta<span class="Sub">2</span>-agonists. Reduction in the use of
rescue short-acting beta<span class="Sub">2</span>-agonists, as compared to placebo, was
demonstrated in one of the two 6-month studies.</p>
<p><span class="Italics"><span class="Emphasis">4-Year Effects on
Lung Function</span></span><br>
A 4-year, randomized, double-blind, placebo-controlled, multicenter clinical trial involving 5992
<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> patients was conducted to evaluate the long-term effects of SPIRIVA
HandiHaler on disease progression (rate of decline in FEV<span class="Sub">1</span>).
Patients were permitted to use all respiratory medications (including
short-acting and long-acting beta-agonists, inhaled and systemic steroids, and
theophyllines) other than inhaled anticholinergics. The patients were 40 to 88
years of age, 75% male, and 90% Caucasian with a diagnosis of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> and a mean pre-bronchodilator
FEV<span class="Sub">1</span> of 39% predicted (range = 9% to 76%) at study entry.  There was
no difference between the groups in either of the co-primary efficacy
endpoints, yearly rate of decline in pre- and post-bronchodilator FEV<span class="Sub">1</span>,
as demonstrated by similar slopes of FEV<span class="Sub">1</span> decline over time (Figure
3). </p>
<p>SPIRIVA HandiHaler
maintained improvements in trough (pre-dose) FEV<span class="Sub">1</span> (adjusted means
over time: 87 to 103 mL) throughout the 4 years of the study (Figure 3).</p>
<p><span class="Bold"><span class="Emphasis">Figure 3 Trough (pre-dose) FEV<span class="Sub">1</span> Mean Values at Each Time Point</span></span></p>
<div class="Figure"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Figure3.jpg"></div>
<p>Repeated measure
ANOVA was used to estimate means. Means are adjusted for baseline measurements.
Baseline trough FEV<span class="Sub">1</span> (observed mean) = 1.12. Patients with ≥3
acceptable pulmonary function tests after Day 30 and non-missing baseline value
were included in the analysis. </p>
<p><span class="Italics"><span class="Emphasis">Exacerbations</span></span><br>
The effect of SPIRIVA HandiHaler on <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span> was evaluated in two
clinical trials: a 4-year clinical trial described above and a 6-month clinical
trial of 1829 <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> patients in a Veterans Affairs setting. In the 6-month
trial, <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span> were defined as a complex of respiratory symptoms
(increase or new onset) of more than one of the following: <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>,
<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, or <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span> with a duration of at least 3 days
requiring treatment with antibiotics, systemic steroids, or hospitalization.  The
population had an age ranging from 40 to 90 years with 99% males, 91%
Caucasian, and had <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> with a mean pre-bronchodilator FEV<span class="Sub">1</span> percent
predicted of 36% (range = 8% to 93%).  Patients were permitted to use
respiratory medications (including short-acting and long-acting beta-agonists,
inhaled and systemic steroids, and theophyllines) other than inhaled
anticholinergics. In the 6-month trial, the co-primary endpoints were the
proportion of patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbation</span> and the proportion of patients
with hospitalization due to <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbation</span>.  SPIRIVA HandiHaler
significantly reduced the proportion of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> patients who experienced
exacerbations compared to placebo (27.9% vs 32.3%, respectively; Odds Ratio (OR)
(tiotropium/placebo) = 0.81; 95% CI = 0.66, 0.99; p = 0.037).  The proportion
of patients with hospitalization due to <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span> in patients who used
SPIRIVA HandiHaler compared to placebo was 7.0% vs 9.5%, respectively; OR =
0.72; 95% CI = 0.51, 1.01; p = 0.056.</p>
<p>Exacerbations were
evaluated as a secondary outcome in the 4-year multicenter trial. In this
trial, <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span> were defined as an increase or new onset of more than
one of the following respiratory symptoms (<span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> purulence,
<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>) with a duration of three or more days requiring treatment
with antibiotics and/or systemic (oral, intramuscular, or intravenous)
steroids.  SPIRIVA HandiHaler significantly reduced the risk of an exacerbation
by 14% (Hazard Ratio (HR) = 0.86; 95% CI = 0.81, 0.91; p&lt;0.001) and reduced
the risk of exacerbation-related hospitalization by 14% (HR = 0.86; 95% CI =
0.78, 0.95; p&lt;0.002) compared to placebo.  The median time to first
exacerbation was delayed from 12.5 months (95% CI = 11.5, 13.8) in the placebo
group to 16.7 months (95% CI = 14.9, 17.9) in the SPIRIVA HandiHaler group.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-14"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">SPIRIVA
HandiHaler consists of SPIRIVA capsules and the HandiHaler device. SPIRIVA capsules
contain 18 mcg of tiotropium and are light green, with the Boehringer Ingelheim
company logo on the SPIRIVA capsule cap and TI 01 on the SPIRIVA capsule body,
or vice versa.</p>
<p>The
HandiHaler device is gray colored with a green piercing button. It is imprinted
with SPIRIVA HandiHaler (tiotropium bromide inhalation powder), the Boehringer
Ingelheim company logo, and the Pfizer company logo. It is also imprinted to
indicate that SPIRIVA capsules should not be stored in the HandiHaler device
and that the HandiHaler device is only to be used with SPIRIVA capsules.</p>
<p>SPIRIVA
capsules are packaged in an aluminum/aluminum <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card and joined along a
perforated-cut line. SPIRIVA capsules should always be stored in the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>
and only removed immediately before use. The drug should be used immediately
after the packaging over an individual SPIRIVA capsule is opened.</p>
<p>The
following packages are available:</p>
<ul>
<li>carton containing 6 SPIRIVA
capsules (5 unit-dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards) and 1 HandiHaler inhalation device (NDC 54868-5109-0)</li>
<li>carton containing 90 SPIRIVA
capsules (9 unit-dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards) and 1 HandiHaler inhalation device (NDC 54868-5109-1)</li>
</ul>
<p><span class="Italics"><span class="Emphasis">Storage</span></span><br><span class="Bold"><span class="Emphasis">Store
at 25°C (77°F); excursions permitted to 15°–30°C (59°–86°F)</span></span> [see USP Controlled Room Temperature].</p>
<p>The SPIRIVA capsules should not be exposed to extreme temperature or moisture. Do
not store SPIRIVA capsules in the HandiHaler device.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-15"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics"><span class="Emphasis">See FDA-approved Patient Labeling <a href="#Section_17.6">(17.6)</a></span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1  Instructions for Administering SPIRIVA HandiHaler</h2>
<p class="First">It
is important for patients to understand how to correctly administer SPIRIVA
capsules using the HandiHaler device [<span class="Italics"><span class="Emphasis">see Patient Counseling Information
<a href="#Section_17.6">(17.6)</a></span></span>]. Patients should be instructed that SPIRIVA capsules should only be
administered via the HandiHaler device and the HandiHaler device should not be
used for administering other medications. <span class="Bold"><span class="Emphasis">The contents of SPIRIVA capsules
are for oral inhalation only and must not be swallowed</span></span>.</p>
<p>SPIRIVA
capsules should always be stored in sealed <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>. Only one SPIRIVA capsule should
be removed immediately before use or its effectiveness may be reduced.
Additional SPIRIVA capsules that are exposed to air (i.e., not intended for
immediate use) should be discarded.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2  Paradoxical <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></h2>
<p class="First">Patients
should be informed that SPIRIVA HandiHaler can produce paradoxical
<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>. If <span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">paradoxical bronchospasm</span> occurs, patients should discontinue
SPIRIVA HandiHaler.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.3"></a><a name="section-15.3"></a><p></p>
<h2>17.3  Urinary Retention</h2>
<p class="First">Difficulty
passing urine and <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span> may be symptoms of new or worsening prostatic
<span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> or bladder outlet obstruction. Patients should be instructed to
consult a physician immediately should any of these signs or symptoms develop.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.4"></a><a name="section-15.4"></a><p></p>
<h2>17.4  Visual Effects</h2>
<p class="First">Eye
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, visual halos or colored images in
association with <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eyes</span> from <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival congestion</span> and <span class="product-label-link" type="condition" conceptid="377875" conceptname="Idiopathic corneal edema">corneal edema</span> may be
signs of acute narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Patients should be told to consult a
physician immediately should any of these signs and symptoms develop. Miotic
eye drops alone are not considered to be effective treatment.</p>
<p>Patients
should be told that care must be taken not to allow the powder to enter into
the eyes as this may cause <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span> and pupil dilation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.5"></a><a name="section-15.5"></a><p></p>
<h2>17.5  Acute Exacerbation</h2>
<p class="First">Patients
should understand that SPIRIVA HandiHaler is a once-daily maintenance
bronchodilator and should not be used for immediate relief of breathing
problems (i.e., as a rescue medication).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.6"></a><a name="section-15.6"></a><p></p>
<h2>17.6  FDA-approved Patient Labeling</h2>
<p class="First">Patient
Information and Patient’s Instructions for Use are supplied as tear-off leaflets
following the full prescribing information and should be dispensed with each
new prescription and refill.</p>
<p>Distributed by:<br>
Boehringer Ingelheim Pharmaceuticals, Inc.<br>
Ridgefield, CT 06877 USA</p>
<p>Marketed by:<br>
Boehringer Ingelheim Pharmaceuticals, Inc.<br>
 Ridgefield, CT 06877 USA<br>
and<br>
Pfizer Inc<br>
New York, NY 10017 USA</p>
<p>Licensed from:<br>
Boehringer Ingelheim International GmbH</p>
<p><span class="Bold"><span class="Emphasis">Address medical inquiries to: (800)
542-6257 or (800) 459-9906 TTY.</span></span></p>
<p>SPIRIVA® and HandiHaler® are registered trademarks and are used under license from Boehringer Ingelheim International
GmbH.</p>
<p>©Copyright 2009 Boehringer Ingelheim International GmbH<br>
ALL RIGHTS RESERVED</p>
<p>SPIRIVA® (tiotropium bromide inhalation powder) is covered by
U.S. Patent Nos. RE38,912, RE39,820, 5,478,578, 6,777,423, 6,908,928, 7,070,800,
and 7,309,707 with other patents pending. The HandiHaler<span class="Sup">®</span> inhalation
device is covered by U.S. Design Patent No. D355,029 with other patents
pending.</p>
<p>Rev:
December 2009</p>
<p>IT1600WL1609<br>
10004551/07<br>
65626-08</p>
<br><p>Relabeling of "Additional Barcode"  by:<br>Physicians Total Care, Inc.<br>Tulsa, OK    74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="Section_18"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">Patient Information</span></span></p>
<p><span class="Bold"><span class="Emphasis">SPIRIVA<span class="Sup">®</span> (speh REE vah) HandiHaler<span class="Sup">®</span><br>(tiotropium bromide inhalation powder)</span></span></p>
<div class="Figure"><img alt="Instructions for SPIRIVA" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Instructions1.jpg"></div>
<p><span class="Bold Underline"><span class="Emphasis">Important Information:</span></span><span class="Bold"><span class="Emphasis"> Do not swallow SPIRIVA capsules.  SPIRIVA capsules should only be used with the HandiHaler device.  SPIRIVA HandiHaler should only be inhaled by mouth (oral inhalation).</span></span></p>
<p>Read the information that comes with your SPIRIVA HandiHaler before you start using it and each time you refill your prescription. There may be new information.  This leaflet does not take the place of talking with your doctor about your medical condition or your treatment.</p>
<p><span class="Bold"><span class="Emphasis">What is SPIRIVA HandiHaler?</span></span><br>
							SPIRIVA HandiHaler is a prescription medicine that you use one time every day (a maintenance medicine) to control symptoms of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>). SPIRIVA HandiHaler helps make your lungs work better for 24 hours. SPIRIVA HandiHaler relaxes your airways and helps keep them open. You may start to feel like it is easier to breathe on the first day, but it may take longer for you to feel the full effects of the medicine.  SPIRIVA HandiHaler works best and may help make it easier to breathe when you use it every day.</p>
<p>SPIRIVA HandiHaler also reduces the likelihood of flare-ups and worsening of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> symptoms (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span>).  A <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbation</span> is defined as an increase or new onset of more than one <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> symptom such as <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, mucus, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> that requires medicine beyond your rescue medicine.</p>
<p>SPIRIVA HandiHaler is <span class="Bold"><span class="Emphasis">not</span></span> a rescue medicine and should not be used for treating sudden breathing problems. Your doctor may give you other medicine to use for sudden breathing problems.</p>
<p>SPIRIVA HandiHaler has not been studied in children.</p>
<p><span class="Bold"><span class="Emphasis">Who should not take SPIRIVA HandiHaler?</span></span></p>
<p><span class="Bold"><span class="Emphasis">Do not use SPIRIVA HandiHaler if you:</span></span></p>
<ul class="Disc">
<li>are allergic to tiotropium. See the end of this leaflet for a complete list of ingredients.</li>
<li>have had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to ipratropium (Atrovent<span class="Sup">®</span>).</li>
</ul>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> may include <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the lips, tongue, or throat (trouble swallowing).</p>
<p><span class="Bold"><span class="Emphasis">What should I tell my doctor before using SPIRIVA HandiHaler?</span></span></p>
<p><span class="Bold"><span class="Emphasis">Before taking SPIRIVA HandiHaler, tell your doctor about all your medical conditions, including if you:</span></span></p>
<ul class="Disc">
<li>have kidney problems.</li>
<li>have <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.  SPIRIVA HandiHaler may make your <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> worse.</li>
<li>have an <span class="product-label-link" type="condition" conceptid="4093346" conceptname="Large prostate">enlarged prostate</span>, problems passing urine, or a blockage in your bladder. SPIRIVA HandiHaler may make these problems worse.</li>
<li>are pregnant or plan to become pregnant. It is not known if SPIRIVA HandiHaler could harm your unborn baby.</li>
<li>are breast-feeding or plan to breast-feed. It is not known if SPIRIVA HandiHaler passes into breast milk. You and your doctor will decide if SPIRIVA HandiHaler is right for you while you breast-feed.</li>
<li>have a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to milk proteins. Ask your doctor if you are not sure.</li>
</ul>
<p><span class="Bold"><span class="Emphasis">Tell your doctor about all the medicines you take,</span></span> including prescription and non-prescription medicines and eye drops, vitamins, and herbal supplements.  Some of your other medicines or supplements may affect the way SPIRIVA HandiHaler works.  SPIRIVA HandiHaler is an anticholinergic medicine. You should not take other anticholinergic medicines while using SPIRIVA HandiHaler, including ipratropium. Ask your doctor or pharmacist if you are not sure if one of your medicines is an anticholinergic.</p>
<p>Know the medicines you take.  Keep a list of your medicines with you to show your doctor and pharmacist when you get a new medicine. </p>
<p><span class="Bold"><span class="Emphasis">How should I take SPIRIVA HandiHaler?</span></span></p>
<ul class="Disc">
<li>Use SPIRIVA HandiHaler exactly as prescribed.  Use SPIRIVA HandiHaler one time every day. </li>
<li>Read the “Patient’s Instructions for Use? at the end of this leaflet before you use SPIRIVA HandiHaler. Talk with your doctor if you do not understand the instructions. </li>
<li><span class="Bold">Do not swallow SPIRIVA capsules. </span></li>
<li><span class="Bold">Only use SPIRIVA capsules with the HandiHaler device.</span></li>
<li><span class="Bold">Do not use the HandiHaler device to take any other medicine</span></li>
<li>SPIRIVA HandiHaler comes as a powder in a SPIRIVA capsule that fits the HandiHaler device. Each SPIRIVA capsule, containing only a small amount of SPIRIVA powder, is one full dose of medicine. </li>
<li>Separate one <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card. Then take out one of the SPIRIVA capsules from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package right before you use it. </li>
<li>After the capsule is pierced, take a complete dose of SPIRIVA HandiHaler by breathing in the powder by mouth two times, using the HandiHaler device (take 2 inhalations from one SPIRIVA capsule). See the “Patient’s Instructions for Use? at the end of this leaflet.</li>
<li>Throw away any SPIRIVA capsule that is not used right away after it is taken out of the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package.  Do not leave the SPIRIVA capsules open to air; they may not work as well. </li>
<li>If you miss a dose, take it as soon as you remember. Do not use SPIRIVA HandiHaler more than one time every 24 hours. </li>
<li>If you use more than your prescribed dose of SPIRIVA HandiHaler, call your doctor or a poison control center.</li>
</ul>
<p><span class="Bold"><span class="Emphasis">What should I avoid while using SPIRIVA HandiHaler?</span></span></p>
<p>Do not let the powder from the SPIRIVA capsule get into your eyes. Your vision may get blurry and the pupil in your eye may get larger (dilate). If this happens, call your doctor.</p>
<p><span class="Bold"><span class="Emphasis">What are the possible side effects of SPIRIVA HandiHaler?</span></span></p>
<p><span class="Bold"><span class="Emphasis">SPIRIVA HandiHaler can cause serious side effects.  If you get any of the following side effects, stop taking SPIRIVA HandiHaler and get medical help right away.</span></span></p>
<ul class="Disc">
<li>
<span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span>. </span></span>Symptoms may include: <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the lips, tongue, or throat (trouble swallowing).</li>
<li>
<span class="Bold"><span class="Emphasis">Sudden narrowing and blockage of the airways into the lungs (<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>).  </span></span>Your breathing suddenly gets worse.</li>
<li>
<span class="Bold"><span class="Emphasis">New or worsened increased pressure in the eyes (acute narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>). </span></span>Symptoms of acute narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> may include: <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, seeing halos (visual halos) or colored images along with <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eyes</span>.</li>
<li>
<span class="Bold"><span class="Emphasis">New or worsened <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. </span></span>Symptoms of blockage in your bladder and/or <span class="product-label-link" type="condition" conceptid="4093346" conceptname="Large prostate">enlarged prostate</span> may include: difficulty passing urine, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">painful urination</span>.</li>
</ul>
<p>Other side effects with SPIRIVA HandiHaler include:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span></li>
<li><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinus infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></li>
<li>non-specific <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span></li>
<li><span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li>increased heart rate</li>
<li><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></li>
</ul>
<p>These are not all the possible side effects with SPIRIVA HandiHaler.  Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>Call your doctor for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold"><span class="Emphasis">How do I store SPIRIVA HandiHaler?</span></span></p>
<ul class="Disc">
<li><span class="Bold"><span class="Emphasis">Do not store SPIRIVA capsules in the HandiHaler device.</span></span></li>
<li>Store SPIRIVA capsules in the sealed <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package at room temperature between 68°F–77°F (20°–25°C).</li>
<li>Keep SPIRIVA capsules away from heat and <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> (do not freeze).</li>
<li>Store SPIRIVA capsules in a dry place. Throw away any unused SPIRIVA capsules that have been open to air.</li>
</ul>
<p>Ask your doctor or pharmacist if you have any questions about storing your SPIRIVA capsules. </p>
<p><span class="Bold"><span class="Emphasis">Keep SPIRIVA HandiHaler, SPIRIVA capsules, and all medicines out of the reach of children.</span></span></p>
<p><span class="Bold"><span class="Emphasis">General information about SPIRIVA HandiHaler</span></span><br>Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflets.  Do not use SPIRIVA HandiHaler for a purpose for which it has not been prescribed.  Do not give SPIRIVA HandiHaler to other people even if they have the same symptoms that you have.  It may harm them.</p>
<p>For more information about SPIRIVA HandiHaler, talk with your doctor. You can ask your doctor or pharmacist for information about SPIRIVA HandiHaler that is written for health professionals.</p>
<p>For more information about SPIRIVA HandiHaler, you may call Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257 or (TTY) 1-800-459-9906.</p>
<p><span class="Bold"><span class="Emphasis">What are the ingredients in SPIRIVA HandiHaler?</span></span></p>
<p>Active ingredient:  tiotropium<br>Inactive ingredient:  lactose monohydrate</p>
<p><span class="Bold"><span class="Emphasis">What is <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">Chronic Obstructive Pulmonary Disease</span>)? </span></span></p>
<p><span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> is a serious <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> that includes <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>, or both. Most <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> is caused by smoking. When you have <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>, your airways become narrow.  So, air moves out of your lungs more slowly. This makes it hard to breathe.</p>
<p>Distributed by:<br>
Boehringer Ingelheim Pharmaceuticals, Inc.<br>
Ridgefield, CT 06877 USA<br></p>
<p>Marketed by:<br>
Boehringer Ingelheim Pharmaceuticals, Inc.<br> 
Ridgefield, CT 06877 USA<br>
and<br>
Pfizer Inc<br>
New York, NY 10017 USA<br></p>
<p>Licensed from:<br>
Boehringer Ingelheim International GmbH
</p>
<p>SPIRIVA<span class="Sup">®</span> and HandiHaler<span class="Sup">®</span> are registered trademarks and are used under license from Boehringer Ingelheim International GmbH.</p>
<p>©Copyright 2009 Boehringer Ingelheim International GmbH<br>
ALL RIGHTS RESERVED 
</p>
<p>Rev: December 2009</p>
<p>IT1600WL1609<br>
10004551/07<br>
65626-08
</p>
<p><span class="Bold"><span class="Emphasis">Patient's Instructions for Use</span></span></p>
<p><span class="Bold"><span class="Emphasis">SPIRIVA HandiHaler<span class="Sup">®</span><br>(tiotropium bromide inhalation powder)</span></span></p>
<div class="Figure"><img alt="Instructions for SPIRIVA" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Instructions2.jpg"></div>
<p><span class="Bold Underline"><span class="Emphasis">Important Information:</span></span><span class="Bold"><span class="Emphasis"> Do not swallow SPIRIVA capsules.  SPIRIVA capsules should only be used with the HandiHaler device.  SPIRIVA HandiHaler should only be inhaled through your mouth (oral inhalation).</span></span></p>
<p>First read the Patient Information that comes with SPIRIVA HandiHaler for important information about using SPIRIVA HandiHaler. </p>
<p>Read these Patient's Instructions for Use before you start to use SPIRIVA HandiHaler and each time you refill your prescription.  There may be new information.</p>
<p>For more information, ask your doctor or pharmacist.</p>
<p>SPIRIVA HandiHaler comes with SPIRIVA capsules and a HandiHaler device. The HandiHaler device is an inhalation device that is for use only with SPIRIVA capsules. Do not use the HandiHaler device to take any other medicine.</p>
<p><span class="Bold"><span class="Emphasis">Becoming familiar with SPIRIVA HandiHaler: </span></span></p>
<a name="i461380c0-c15e-446e-8ef9-9bb16b1370df"></a><table border="0" cellpadding="0" cellspacing="0" width="90%"><tbody class="Headless">
<tr class="First">
<td><img alt="Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=FigureA.jpg"></td>
<td align="left">Remove the HandiHaler device from the pouch and become familiar with its components. (Figure A)<br><ol class="Disc">
<li>dust cap</li>
<li>mouthpiece</li>
<li>mouthpiece ridge</li>
<li>base</li>
<li>green piercing button</li>
<li>center chamber</li>
<li>air intake vents</li>
</ol>
</td>
</tr>
<tr>
<td><img alt="Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=FigureB.jpg"></td>
<td align="left">Each SPIRIVA capsule is packaged in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>. Each <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> can be separated from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card by tearing along the perforation. (Figure B)</td>
</tr>
<tr>
<td><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=FigureC.jpg"></td>
<td align="left"><p class="First"><span class="Bold">Do not open the SPIRIVA capsule </span>before you insert it into the HandiHaler device. If you open the SPIRIVA capsule, it may not work. Each SPIRIVA capsule contains only a small amount of powder. (Figure C) This is one full dose. The product was designed this way. </p></td>
</tr>
<tr><td align="left" colspan="2">
<p class="First"><span class="Bold">How do I inhale the contents of the SPIRIVA capsule using the HandiHaler device?</span></p>
<br><p>Taking your dose of medicine using the <span class="Underline">HandiHaler</span> device has four main steps:</p>
<ol class="Disc">
<li>
<span class="Bold">Open</span> the HandiHaler device and the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span></li>
<li>
<span class="Bold">Insert</span> the SPIRIVA capsule</li>
<li>
<span class="Bold">Press</span> the green piercing button</li>
<li>
<span class="Bold">Breathe in (inhale)</span> your medicine</li>
</ol>
<br>
										(See below for details)<br><br>
</td></tr>
<tr><td><p class="First"><span class="Bold">Opening the HandiHaler device:<br><br></span></p></td></tr>
<tr>
<td><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Figure1A.jpg"></td>
<td align="left"><p class="First"><span class="Bold">1. Open</span> the dust cap by pressing the green piercing button. (Figure 1)</p></td>
</tr>
<tr>
<td><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Figure2A.jpg"></td>
<td align="left">Pull the dust cap upwards to expose the mouthpiece. (Figure 2)</td>
</tr>
<tr>
<td>
<img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Figure3A.jpg"><br><br>
</td>
<td align="left">Open the mouthpiece by pulling the mouthpiece ridge upwards away from the base. (Figure 3)</td>
</tr>
<tr><td align="left" colspan="2"><p class="First"><span class="Bold">Removing a SPIRIVA capsule:</span></p></td></tr>
<tr>
<td><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Figure4.jpg"></td>
<td align="left">
<p class="First">Before removing a SPIRIVA capsule from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>, separate one of the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card by tearing along the perforation. (Figure 4)<br><br></p>
<p><span class="Bold">Do not swallow SPIRIVA capsules.<br><br></span></p>
<p><span class="Bold">Always store SPIRIVA capsules in the sealed <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>. Remove only one SPIRIVA capsule from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> right before use. Do not store SPIRIVA capsules in the HandiHaler device. Inhale the contents of the SPIRIVA capsule using the HandiHaler device right away after the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packaging of an individual SPIRIVA capsule is opened, or else it may not work as well.</span></p>
</td>
</tr>
<tr>
<td><img alt="Figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Figure5.jpg"></td>
<td align="left">
<p class="First">Right before you are ready to use your SPIRIVA HandiHaler:<br><br></p>
<p>Bend back and forth one of the corners of the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> that has an arrow and then with your finger separate the aluminum foil layers. Carefully peel back the printed foil until you can see the whole SPIRIVA capsule. (Figure 5)<br><br></p>
<p>Turn the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> upside down and tip the SPIRIVA capsule out, tapping the back of the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>, if needed.<br><br></p>
<p><span class="Bold">Do not cut the foil or use sharp instruments to take out the SPIRIVA capsule from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>.<br><br></span></p>
<p><span class="Bold">If more SPIRIVA capsules are opened to air, they should not be used and should be thrown away.</span></p>
</td>
</tr>
<tr><td align="left" colspan="2"><p class="First"><span class="Bold"><br><br>Inserting the SPIRIVA capsule into the HandiHaler device:<br><br></span></p></td></tr>
<tr>
<td><img alt="Figure 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Figure6.jpg"></td>
<td align="left"><p class="First"><span class="Bold">2. Insert</span> (put) the SPIRIVA capsule in the center chamber of the HandiHaler device. It does not matter which end of the SPIRIVA capsule you put in the chamber. (Figure 6)</p></td>
</tr>
<tr>
<td><img alt="Figure 7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Figure7.jpg"></td>
<td align="left"><p class="First">Close the mouthpiece <span class="Bold">until you hear a click,</span> but leave the dust cap open. (Figure 7)<br><br>Be sure that you have the mouthpiece sitting firmly against the gray base.</p></td>
</tr>
<tr><td align="left" colspan="2"><p class="First"><span class="Bold"><br><br>Taking your dose using the HandiHaler device:<br><br></span></p></td></tr>
<tr>
<td>
<img alt="Figure 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Figure8.jpg">`
									</td>
<td align="left">
<p class="First"><span class="Bold">Hold the HandiHaler device with the mouthpiece upright. It is important that you hold the HandiHaler device in an upright position (Figure 8) when pressing the green piercing button.<br><br></span></p>
<p><span class="Bold">3.  Press the green piercing button until it is flat (flush) against the base, and release.</span> This is how you make holes in the SPIRIVA capsule so that you get the medicine when you breathe in.<br><br></p>
<p><span class="Bold Underline">Do not press the green button more than one time.</span></p>
</td>
</tr>
<tr>
<td><img alt="Figure 9" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Figure9.jpg"></td>
<td align="left">
<p class="First"><span class="Bold">Breathe out completely. </span>(Figure 9) <br><br></p>
<p><span class="Bold">Important:</span> Do not breathe (exhale) into the mouthpiece of the HandiHaler device at any time. </p>
</td>
</tr>
<tr>
<td><img alt="Figure 10" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Figure10.jpg"></td>
<td align="left">
<p class="First"><span class="Bold">4.  Breathe in (inhale)</span></p>
<ul class="Disc">
<li>Hold the HandiHaler device by the gray base. Do not block the air intake vents. </li>
<li>Raise the HandiHaler device to your mouth and close your lips tightly around the mouthpiece. </li>
<li>
<span class="Bold">Keep your head in an upright position.  The HandiHaler device should be in a horizontal position.</span> (Figure 10)</li>
<li>Breathe in <span class="Bold">slowly and deeply</span> so that you <span class="Bold">hear or feel the SPIRIVA capsule vibrate.</span>
</li>
<li>Breathe in until your lungs are full. </li>
<li>Hold your breath as long as is comfortable and at the same time take the HandiHaler device out of your mouth. Breathe normally again. </li>
</ul>
</td>
</tr>
<tr><td align="left" colspan="2">
<span class="Bold"><br><br>To make sure you get the full dose, you must breathe out completely, and inhale again as in step 4 above (Figure 10).</span><span class="Bold Italics"> Do not press the green piercing button again.<br><br></span>
</td></tr>
<tr>
<td><img alt="Figure 11" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Figure11.jpg"></td>
<td align="left">
<p class="First">If you do not hear or feel the SPIRIVA capsule vibrate, <span class="Bold Underline">do not press the green piercing button again.</span> Instead, hold the HandiHaler device in an upright position and tap the HandiHaler device gently on a table. (Figure 11)<br><br></p>
<p>Check to see that the mouthpiece is completely closed. Then, breathe in again – slowly and deeply.<br><br></p>
<p>If you still do not hear or feel the SPIRIVA capsule vibrate after repeating the above steps, throw away the SPIRIVA capsule. Open the base by lifting the green piercing button and check the center chamber for pieces of the SPIRIVA capsule (SPIRIVA capsule fragments). SPIRIVA capsule fragments in the center chamber can cause a SPIRIVA capsule not to vibrate. Turn the HandiHaler device upside down and gently tap to remove the SPIRIVA capsule fragments. Call your doctor for instructions.</p>
</td>
</tr>
<tr>
<td><img alt="Figure 12" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Figure12.jpg"></td>
<td align="left"><p class="First">After you finish taking your daily dose of SPIRIVA HandiHaler, open the mouthpiece again. Tip out the used SPIRIVA capsule and throw it away. 
(Figure 12)</p></td>
</tr>
<tr>
<td><img alt="Figure 13" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Figure13.jpg"></td>
<td align="left">
<p class="First">Close the mouthpiece and dust cap for storage of your HandiHaler device. (Figure 13)<br><br></p>
<p><span class="Bold">Do not store used or unused SPIRIVA capsules in the HandiHaler device.</span></p>
</td>
</tr>
<tr><td colspan="2"><p class="First"><span class="Bold"><br><br>When and how should I clean my HandiHaler device?</span></p></td></tr>
<tr class="Last">
<td><img alt="Figure 14" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=Figure14.jpg"></td>
<td align="left">
<p class="First">Clean the HandiHaler device one time each month or as needed. (Figure 14)</p>
<ul class="Disc">
<li>Open the dust cap and mouthpiece.</li>
<li>Open the base by lifting the green piercing button. </li>
<li>Look at the center chamber for SPIRIVA capsule fragments or powder residue.</li>
<li>Rinse the HandiHaler device with warm water. Check that any powder buildup or SPIRIVA capsule fragments are removed.</li>
<li>Do not use cleaning agents or detergents. </li>
<li>Do not place the HandiHaler device in the dishwasher for cleaning.</li>
<li>Dry the HandiHaler device well by tipping the excess water out on a paper towel. Air-dry afterwards, leaving the dust cap, mouthpiece, and base open.</li>
<li>Do not use a hair dryer to dry the HandiHaler device.</li>
<li><span class="Bold">It takes 24 hours to air dry, so clean the HandiHaler device right after you use it so that it will be ready for your next dose.</span></li>
<li>Do not use the HandiHaler device when it is wet. If needed, you may clean the outside of the mouthpiece with a clean damp cloth.</li>
</ul>
</td>
</tr>
</tbody></table>
<p>Distributed by:<br>
Boehringer Ingelheim Pharmaceuticals, Inc.<br>
Ridgefield, CT 06877 USA
</p>
<p>Marketed by:<br>
Boehringer Ingelheim Pharmaceuticals, Inc.<br>
Ridgefield, CT 06877 USA<br>
and<br>
Pfizer Inc<br>
New York, NY 10017 USA
</p>
<p>Licensed from:<br>
Boehringer Ingelheim International GmbH
</p>
<p>SPIRIVA<span class="Sup">®</span> and HandiHaler<span class="Sup">®</span> are registered trademarks and are used under license from Boehringer Ingelheim International GmbH</p>
<p>©Copyright 2009 Boehringer Ingelheim International GmbH<br>
ALL RIGHTS RESERVED
</p>
<p>Rev: December 2009</p>
<p>IT1600WL1609<br>
10004551/07<br>
65626-08
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_19"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First">SPIRIVA HandiHaler</p>
<p>30 capsules (5 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards)</p>
<p>1 HandiHaler Inhalation Device</p>
<div class="Figure"><img alt="SPIRIVA HandiHaler 30 capsules" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cf82d42-5ad0-4b86-838e-9230c61cf3d4&amp;name=package%20label.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SPIRIVA 		
					</strong><br><span class="contentTableReg">tiotropium bromide monohydrate capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5109(NDC:0597-0075)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL, RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TIOTROPIUM BROMIDE MONOHYDRATE</strong> (TIOTROPIUM) </td>
<td class="formItem">TIOTROPIUM BROMIDE MONOHYDRATE</td>
<td class="formItem">18 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">green</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Tl;01</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5109-0</td>
<td class="formItem">5  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">6  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5109-1</td>
<td class="formItem">9  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021395</td>
<td class="formItem">07/14/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ca587c20-50ac-4f59-96f6-5b1e1505722f</div>
<div>Set id: 1cf82d42-5ad0-4b86-838e-9230c61cf3d4</div>
<div>Version: 3</div>
<div>Effective Time: 20100318</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
